Immunovant Inc.
Organization details
- Legal name
- Immunovant Inc.
- Former names
- Health Sciences Acquisitions Corp
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Durham
- Headquarters state / province
- North Carolina
- Headquarters country
- United States
- Fiscal year end
- March
- Ticker symbol
- IMVT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001764013
- EIN
- 83-2771572
Board of directors
-
Andrew J. Fromkin · DirectorSince 2023
-
Atul Pande · DirectorSince 2023
-
Douglas J. Hughes · DirectorSince 2023
-
Eric Venker · Director · Chief Executive OfficerSince 2025
-
Frank Torti · DirectorSince 2023
-
George Migausky V · DirectorSince 2023
-
Jake Bauer · DirectorSince 2025
-
Peter Salzmann · Director · Chief Executive OfficerSince 2023
-
Robert Graham Susman · DirectorSince 2025
Chief executives
Director election results
Annual meeting of September 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
86.0%
-
91.9%
-
95.9%
Board connections
4 of this board's directors also sit on 5 other boards. 5 are in the same sector.
-
Arbutus Biopharma Corporation Same sectorvia Frank Torti
-
BridgeBio Oncology Therapeutics Inc. Same sectorvia Jake Bauer
-
Corbus Pharmaceuticals Holdings Inc. Same sectorvia Peter Salzmann
-
Enliven Therapeutics Inc. Same sectorvia Jake Bauer
-
REGENXBIO Inc. Same sectorvia George Migausky V
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $349,999,986
- 1 purchase by 1 insider
- Sold, last 12 months
- $16,504,285
- 62 sales by 9 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 28, 2026 | Girao Tiago Officer (Chief Financial Officer) | Open-market sale | −6,606 | $28.50 | $188,271 |
| Oct 21, 2026 | Stout Jay S Officer (Chief Technology Officer) | Open-market sale | −2,595 | $28.94 | $75,099 |
| Oct 7, 2026 | Gloria Melanie Officer (Chief Operating Officer) | Open-market sale | −2,241 | $32.06 | $71,846 |
| Oct 7, 2026 | Stout Jay S Officer (Chief Technology Officer) | Open-market sale | −2,213 | $32.06 | $70,949 |
| Oct 7, 2026 | Van Tuyl Christopher Officer (Chief Legal Officer) | Open-market sale | −1,327 | $32.06 | $42,544 |
| Oct 7, 2026 | Stout Jay S Officer (Chief Technology Officer) | Open-market sale | −1,596 | $32.06 | $51,168 |
| Oct 2, 2026 | Eric Venker Director, Officer (Chief Executive Officer) | Open-market sale | −3,506 | $34.11 | $119,590 |
| Oct 1, 2026 | Eric Venker Director, Officer (Chief Executive Officer) | Option exercise | +92,187 | $14.46 | $1,333,024 |
| Oct 1, 2026 | Eric Venker Director, Officer (Chief Executive Officer) | Sold back to the company | −85,886 | $33.65 | $2,890,064 |
| Sep 23, 2026 | Van Tuyl Christopher Officer (Chief Legal Officer) | Open-market sale | −2,846 | $36.36 | $103,481 |
| Aug 28, 2026 | Atul Pande Director | Option exercise | +1,500 | $8.43 | $12,645 |
| Aug 28, 2026 | Atul Pande Director | Open-market sale | −1,500 | $43.27 | $64,905 |
| Aug 20, 2026 | Gloria Melanie Officer (Chief Operating Officer) | Open-market sale | −3,056 | $44.16 | $134,953 |
| Jul 24, 2026 | Atul Pande Director | Option exercise | +1,500 | $8.43 | $12,645 |
| Jul 24, 2026 | Atul Pande Director | Open-market sale | −1,500 | $39.80 | $59,700 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Immunovant Inc.
Who is the CEO of Immunovant Inc.?
Peter Salzmann is Immunovant Inc.'s Chief Executive Officer.
How many directors are on Immunovant Inc.'s board?
Immunovant Inc.'s board has 9 directors: Andrew J. Fromkin, Atul Pande, Douglas J. Hughes, Eric Venker, Frank Torti, George Migausky V, Jake Bauer, Peter Salzmann and Robert Graham Susman.
Are Immunovant Inc. insiders buying or selling shares?
Over the last 12 months, Immunovant Inc. insiders bought $350.0 million of shares in 1 purchase and sold $16.5 million of shares in 62 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="immunovant-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.